Catalyst

Slingshot members are tracking this event:

Ardelyx'S Plans to Initiate The Second Phase 3 Study of Tenapanor for The Treatment Of Hyperphosphatemia in ESRD Patients on Dialysis in Mid-2017

Source Link:
http://www.prnewswire.com/news-releases/ardelyx-announces-successful-phase-3-trial-of-tenapanor-for-hyperphosphatemia-in-patients-with-end-stage-renal-disease-300407693.html

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ARDX Community voting in process
KERX Community voting in process
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Feb 15, 2017
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Tenapanor, End-stage Renal Disease, Esrd, Hyperphosphatemia
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.